Do analysts rate KTTA or ALBT?

Pasithea Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 383.87%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KTTA or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Avalon GloboCare N/A N/A -74.36%

Does the media prefer KTTA or ALBT?

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for Avalon GloboCare. Pasithea Therapeutics' average media sentiment score of 1.29 beat Avalon GloboCare's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MTVA or ALBT?

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 716.33%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MTVA or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Avalon GloboCare N/A N/A -74.36%

Does the media favor MTVA or ALBT?

In the previous week, MetaVia and MetaVia both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.93 beat MetaVia's score of 0.43 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend QCLS or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QCLS or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Avalon GloboCare N/A N/A -74.36%

Do analysts prefer NAII or ALBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer NAII or ALBT?

In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.93 beat Natural Alternatives International's score of 0.47 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natural Alternatives International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer COCP or ALBT?

Cocrystal Pharma currently has a consensus target price of $6.00, indicating a potential upside of 468.72%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cocrystal Pharma is more favorable than Avalon GloboCare. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is COCP or ALBT more profitable?

Avalon GloboCare's return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Avalon GloboCare N/A N/A -74.36%

Does the media prefer COCP or ALBT?

In the previous week, Cocrystal Pharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for Cocrystal Pharma and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.93 beat Cocrystal Pharma's score of 0.22 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Avalon GloboCare (ALBT) Competitors

$0.35 -0.02 (-5.50%)

Closing price 06/4/2026 04:00 PM Eastern

Extended Trading

$0.35 +0.00 (+0.28%)

As of 06/4/2026 07:58 PM Eastern

Compare

ALBT vs. KTTA, MTVA, QCLS, NAII, and COCP

Should you buy Avalon GloboCare stock or one of its competitors? MarketBeat compares Avalon GloboCare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalon GloboCare include Pasithea Therapeutics (KTTA), MetaVia (MTVA), Mymd Pharmaceuticals (QCLS), Natural Alternatives International (NAII), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry.

How does Avalon GloboCare compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 1 mentions for Avalon GloboCare. Pasithea Therapeutics' average media sentiment score of 1.29 beat Avalon GloboCare's score of 0.93 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Pasithea Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Pasithea Therapeutics currently has a consensus price target of $3.00, indicating a potential upside of 383.87%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avalon GloboCare has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Avalon GloboCare	$1.26M	3.37	-$18.26M	-$3.51	N/A

Avalon GloboCare's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Avalon GloboCare	N/A	N/A	-74.36%

Summary

Pasithea Therapeutics beats Avalon GloboCare on 9 of the 14 factors compared between the two stocks.

How does Avalon GloboCare compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 716.33%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.4% of MetaVia shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Avalon GloboCare's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Avalon GloboCare	N/A	N/A	-74.36%

In the previous week, MetaVia and MetaVia both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.93 beat MetaVia's score of 0.43 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia has higher earnings, but lower revenue than Avalon GloboCare. MetaVia is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Avalon GloboCare	$1.26M	3.37	-$18.26M	-$3.51	N/A

MetaVia has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Summary

Avalon GloboCare beats MetaVia on 8 of the 13 factors compared between the two stocks.

How does Avalon GloboCare compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Avalon GloboCare had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 1 mentions for Avalon GloboCare and 0 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Avalon GloboCare's score of 0.93 indicating that Mymd Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mymd Pharmaceuticals	Very Positive
Avalon GloboCare	Positive

Avalon GloboCare's return on equity of 0.00% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Avalon GloboCare	N/A	N/A	-74.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mymd Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Mymd Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Avalon GloboCare	$1.26M	3.37	-$18.26M	-$3.51	N/A

Summary

Mymd Pharmaceuticals and Avalon GloboCare tied by winning 5 of the 10 factors compared between the two stocks.

How does Avalon GloboCare compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Natural Alternatives International has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Natural Alternatives International has higher revenue and earnings than Avalon GloboCare. Natural Alternatives International is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$129.86M	0.12	-$13.57M	-$2.39	N/A
Avalon GloboCare	$1.26M	3.37	-$18.26M	-$3.51	N/A

In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 0.93 beat Natural Alternatives International's score of 0.47 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natural Alternatives International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalon GloboCare has a net margin of 0.00% compared to Natural Alternatives International's net margin of -10.13%. Avalon GloboCare's return on equity of 0.00% beat Natural Alternatives International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-10.13%	-12.21%	-5.30%
Avalon GloboCare	N/A	N/A	-74.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Natural Alternatives International and Avalon GloboCare tied by winning 6 of the 12 factors compared between the two stocks.

How does Avalon GloboCare compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Cocrystal Pharma has higher earnings, but lower revenue than Avalon GloboCare. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Avalon GloboCare	$1.26M	3.37	-$18.26M	-$3.51	N/A

In the previous week, Cocrystal Pharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 3 mentions for Cocrystal Pharma and 1 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.93 beat Cocrystal Pharma's score of 0.22 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalon GloboCare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cocrystal Pharma currently has a consensus target price of $6.00, indicating a potential upside of 468.72%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cocrystal Pharma is more favorable than Avalon GloboCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 24.2% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avalon GloboCare's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Avalon GloboCare	N/A	N/A	-74.36%

Summary

Cocrystal Pharma beats Avalon GloboCare on 9 of the 14 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALBT vs. The Competition

Export

Metric	Avalon GloboCare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.49M	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.37%	2.69%	5.33%
P/E Ratio	-0.10	18.46	24.03	24.35
Price / Sales	3.37	323.50	522.01	113.27
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	-0.09	6.77	9.98	6.72
Net Income	-$18.26M	$24.09M	$3.56B	$337.03M
7 Day Performance	-1.40%	-3.20%	-1.01%	-0.13%
1 Month Performance	-16.19%	0.36%	2.23%	3.76%
1 Year Performance	-89.68%	49.44%	29.09%	34.36%

Avalon GloboCare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALBT Avalon GloboCare	0.7823 of 5 stars	$0.35 -5.5%	N/A	-89.9%	$4.49M	$1.26M	N/A	5	News Coverage Gap Up
KTTA Pasithea Therapeutics	2.8295 of 5 stars	$0.68 0.0%	$3.00 +341.2%	-32.0%	$16.96M	N/A	N/A	3	Positive News
MTVA MetaVia	2.3951 of 5 stars	$3.27 +10.2%	$20.00 +511.2%	-67.6%	$16.90M	N/A	N/A	8	High Trading Volume
QCLS Mymd Pharmaceuticals	1.1676 of 5 stars	$3.95 +0.3%	N/A	N/A	$16.46M	N/A	N/A	6	Positive News
NAII Natural Alternatives International	1.5648 of 5 stars	$2.61 +2.4%	N/A	-26.0%	$16.39M	$129.86M	N/A	290	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALBT) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalon GloboCare (ALBT) Competitors

ALBT vs. KTTA, MTVA, QCLS, NAII, and COCP

How does Avalon GloboCare compare to Pasithea Therapeutics?

Summary

How does Avalon GloboCare compare to MetaVia?

Summary

How does Avalon GloboCare compare to Mymd Pharmaceuticals?

Summary

How does Avalon GloboCare compare to Natural Alternatives International?

Summary

How does Avalon GloboCare compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalon GloboCare (ALBT) Competitors

ALBT vs. KTTA, MTVA, QCLS, NAII, and COCP

How does Avalon GloboCare compare to Pasithea Therapeutics?

Does the media prefer KTTA or ALBT?

Do institutionals and insiders have more ownership in KTTA or ALBT?

Which has more risk & volatility, KTTA or ALBT?

Do analysts rate KTTA or ALBT?

Which has preferable earnings and valuation, KTTA or ALBT?

Is KTTA or ALBT more profitable?

Summary

How does Avalon GloboCare compare to MetaVia?

Do analysts rate MTVA or ALBT?

Do institutionals & insiders believe in MTVA or ALBT?

Is MTVA or ALBT more profitable?

Does the media favor MTVA or ALBT?

Which has better earnings and valuation, MTVA or ALBT?

Which has more risk and volatility, MTVA or ALBT?

Summary

How does Avalon GloboCare compare to Mymd Pharmaceuticals?

Does the media prefer QCLS or ALBT?

Is QCLS or ALBT more profitable?

Do analysts recommend QCLS or ALBT?

Do institutionals & insiders have more ownership in QCLS or ALBT?

Which has more risk & volatility, QCLS or ALBT?

Which has stronger earnings & valuation, QCLS or ALBT?

Summary

How does Avalon GloboCare compare to Natural Alternatives International?

Do insiders and institutionals hold more shares of NAII or ALBT?

Which has more volatility and risk, NAII or ALBT?

Which has preferable earnings and valuation, NAII or ALBT?

Does the media prefer NAII or ALBT?

Is NAII or ALBT more profitable?

Do analysts prefer NAII or ALBT?

Summary

How does Avalon GloboCare compare to Cocrystal Pharma?

Which has more volatility & risk, COCP or ALBT?

Which has better earnings and valuation, COCP or ALBT?

Does the media prefer COCP or ALBT?

Do analysts prefer COCP or ALBT?

Do insiders & institutionals believe in COCP or ALBT?

Is COCP or ALBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALBT vs. The Competition

Avalon GloboCare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools